Media coverage about Novan (NASDAQ:NOVN) has trended somewhat negative on Thursday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Novan earned a news impact score of -0.02 on Accern’s scale. Accern also assigned media stories about the company an impact score of 42.7981101857506 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the news articles that may have effected Accern’s analysis:

A number of research firms recently issued reports on NOVN. ValuEngine raised Novan from a “strong sell” rating to a “sell” rating in a research report on Friday, September 15th. Zacks Investment Research raised Novan from a “sell” rating to a “hold” rating in a research report on Wednesday, October 4th. Finally, Wedbush reaffirmed a “neutral” rating and issued a $6.00 target price on shares of Novan in a research report on Monday, September 25th.

Shares of Novan (NASDAQ:NOVN) traded down $0.04 during midday trading on Thursday, reaching $4.30. The company’s stock had a trading volume of 61,300 shares, compared to its average volume of 51,650. The firm has a market capitalization of $69.40, a P/E ratio of -0.54 and a beta of 5.15. Novan has a 1 year low of $3.52 and a 1 year high of $27.19.

COPYRIGHT VIOLATION WARNING: “Somewhat Negative Press Coverage Somewhat Unlikely to Impact Novan (NOVN) Share Price” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another site, it was copied illegally and reposted in violation of U.S. & international copyright laws. The correct version of this article can be accessed at

Novan Company Profile

Novan, Inc is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs).

Insider Buying and Selling by Quarter for Novan (NASDAQ:NOVN)

Receive News & Ratings for Novan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novan and related companies with's FREE daily email newsletter.